Tocqueville Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Tocqueville Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-877	Closed	-$872K	–	778
2019 Q1	$872K	Buy	877 +404	+85%	+$375K	0.01%	496
2018 Q4	$411K	Buy	473 +40	+9%	+$37.1K	0.01%	584
2018 Q3	$448K	Buy	433 +40	+10%	+$39.1K	0.01%	640
2018 Q2	$361K	Buy	393 +52	+15%	+$55.9K	﹤0.01%	659
2018 Q1	$332K	Buy	+341	New	+$311K	﹤0.01%	687
2016 Q1	–	Sell	-460	Closed	-$304K	–	865
2015 Q4	$304K	Sell	460 -901	-66%	-$682K	﹤0.01%	769
2015 Q3	$1.07M	Buy	1,361 +1,101	+423%	+$1.34M	0.01%	551
2015 Q2	$343K	Buy	+260	New	+$298K	﹤0.01%	808

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Tocqueville Asset Management's ATRA Position: Q2 2019 in Review

Tocqueville Asset Management sold out of Atara Biotherapeutics (ATRA) in Q2 2019, closing a stake of 877 shares — an estimated $872K sold.

Tocqueville Asset Management first reported a position in ATRA in Q2 2015 and held it in 8 quarters. The position peaked at $1.07M in Q3 2015. 116 funds tracked by Wall St. Rank hold ATRA as of Q2 2019.

Tocqueville Asset Management reported no remaining Atara Biotherapeutics position as of Q2 2019 after selling out during the quarter.
Tocqueville Asset Management sold 877 Atara Biotherapeutics shares in Q2 2019, an estimated $872K.
Tocqueville Asset Management first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 8 quarters.
Tocqueville Asset Management's Atara Biotherapeutics position peaked at $1.07M in Q3 2015.
116 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2019.

Based on Tocqueville Asset Management's 13F filing for Q2 2019, filed 31 Jul 2019.